KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Weighted Average) (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $447.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 63.18% year-over-year to $447.4 million, compared with a TTM value of $447.4 million through Dec 2025, up 63.18%, and an annual FY2025 reading of $447.4 million, up 63.18% over the prior year.
  • Shares Outstanding (Weighted Average) was $447.4 million for Q4 2025 at Recursion Pharmaceuticals, roughly flat from $447.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $447.4 million in Q4 2025 and bottomed at $23.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $229.1 million, with a median of $203.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 6.45% in 2021, then skyrocketed 640.98% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $125.3 million in 2021, then surged by 40.04% to $175.5 million in 2022, then grew by 18.41% to $207.9 million in 2023, then skyrocketed by 31.92% to $274.2 million in 2024, then surged by 63.18% to $447.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for RXRX at $447.4 million in Q4 2025, $447.0 million in Q3 2025, and $410.3 million in Q2 2025.